دورية أكاديمية

Tocilizumab treatment in severe COVID-19: A multicenter retrospective study with matched controls

التفاصيل البيبلوغرافية
العنوان: Tocilizumab treatment in severe COVID-19: A multicenter retrospective study with matched controls
المؤلفون: Mert, Ali, Vahaboğlu, Haluk, Arslan, Ferhat, Batirel, Ayşe, Saraçoğlu, Kemal Tolga, Baştuğ, Aliye, Çağatay, Atahan, Irmak, İlim, Telli Dizman, Gülçin, Ertenli, İhsan, Altunal, Lütfiye Nilsun, Ertürk Şengel, Buket, Bayram, Mehmet, Omma, Ahmet, Amikishiyev, Shirkhan, Aypak, Adalet, Bes, Cemal, Bölükçü, Sibel, İçten, Sacit, Topeli, Arzu, Bektaş, Murat, Arslan, Birsen Yiğit, Öztürk, Sinan, Çomoğlu, Şenol, Aydın, Selda, Küçükşahin, Orhan, İçaçan, Ozan Cemal, İnce, Burak, Aghamuradov, Sarvan, Yalçın Mutlu, Melek, Şimşek, Funda, Emre, Salih, Üstün, Cemal, Ergen, Pınar, Aydın, Özlem, Koç, Meliha Meriç, Sevindik, Ömür Gökmen, Odabaşı, Zekaver, Korten, Volkan, Bodur, Hürrem, Güner, Rahmet, Ünal, Serhat, Koçak, Mehmet, Gül, Ahmet
بيانات النشر: Springer Heidelberg
سنة النشر: 2022
المجموعة: İstanbul Medipol University Institutional Repository (DSpace@Medipol)
مصطلحات موضوعية: COVID-19, Tocilizumab, Interleukin-6 (IL-6), Macrophage Activation Syndrome, Cytokine Storm, Pneumonia, Acute Respiratory Distress Syndrome
الوصف: Coronavirus disease-2019 (COVID-19) associated pneumonia may progress into acute respiratory distress syndrome (ARDS). Some patients develop features of macrophage activation syndrome (MAS). Elevated levels of IL-6 were reported to be associated with severe disease, and anti-IL-6R tocilizumab has been shown to be effective in some patients. This retrospective multicenter case–control study aimed to evaluate the efficacy of tocilizumab in hospitalized COVID-19 patients, who received standard of care with or without tocilizumab. Primary outcome was the progression to intubation or death. PSMATCH (SAS) procedure was used to achieve exact propensity score (PS) matching.Data from 1289 patients were collected, and study population was reduced to 1073 based on inclusion–exclusion criteria. The composite outcome was observed more frequently in tocilizumab-users, but there was a significant imbalance between arms in all critical parameters. Primary analyses were carried out in 348 patients (174 in each arm) after exact PS matching according to gender, ferritin, and procalcitonin. Logistic regression models revealed that tocilizumab significantly reduced the intubation or death (OR 0.40, p = 0.0017). When intubation is considered alone, tocilizumab-users had > 60% reduction in odds of intubation. Multiple imputation approach, which increased the size of the matched patients up to 506, provided no significant difference between arms despite a similar trend for intubation alone group. Analysis of this retrospective cohort showed more frequent intubation or death in tocilizumab-users, but PS-matched analyses revealed significant results for supporting tocilizumab use overall in a subset of patients matched according to gender, ferritin and procalcitonin levels.
نوع الوثيقة: article in journal/newspaper
وصف الملف: application/pdf
اللغة: English
تدمد: 0172-8172
1437-160X
العلاقة: Rheumatology International; Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı; Mert, A., Vahaboğlu, H., Arslan, F., Batirel, A., Saraçoğlu, K. T., Baştuğ, A. . Gül, A. (2022). Tocilizumab treatment in severe COVID-19: A multicenter retrospective study with matched controls. Rheumatology International, 42(3), 457-467. https://dx.doi.org/10.1007/s00296-021-04965-6Test; https://dx.doi.org/10.1007/s00296-021-04965-6Test; https://hdl.handle.net/20.500.12511/10328Test; 42; 457; 467; Q3; 000695386300001; 2-s2.0-85114767140; Q2
DOI: 10.1007/s00296-021-04965-6
الإتاحة: https://doi.org/20.500.12511/10328Test
https://doi.org/10.1007/s00296-021-04965-6Test
https://hdl.handle.net/20.500.12511/10328Test
حقوق: info:eu-repo/semantics/openAccess
رقم الانضمام: edsbas.F1C7B7A4
قاعدة البيانات: BASE
الوصف
تدمد:01728172
1437160X
DOI:10.1007/s00296-021-04965-6